What is he best known for?
The fields of study he is best known for:
His primary areas of study are Molecular biology, Antibody, Cancer research, Monoclonal antibody and Antigen.
Mark I. Greene has included themes like Receptor, Cell surface receptor, Idiotype, Epitope and Gene product in his Molecular biology study.
His studies in Antibody integrate themes in fields like Oncogene, 3T3 cells, In vivo and Immunotherapy.
His research in Cancer research intersects with topics in Cancer, Protein tyrosine phosphatase, Transcription factor, Tumor suppressor gene and FOXP3.
His Monoclonal antibody research is multidisciplinary, incorporating perspectives in Cell culture, Biochemistry, Peptide and Tumor antigen.
His Antigen study necessitates a more in-depth grasp of Immunology.
His most cited work include:
- The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. (979 citations)
- Deacetylase inhibition promotes the generation and function of regulatory T cells (696 citations)
- Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer (618 citations)
What are the main themes of his work throughout his whole career to date?
Mark I. Greene mainly focuses on Molecular biology, Immunology, Cell biology, Antigen and Antibody.
The study incorporates disciplines such as Cell culture, Receptor, Spleen, Idiotype and Epitope in addition to Molecular biology.
He combines subjects such as Suppressor, Cancer research and In vivo with his study of Immunology.
His Cell biology research focuses on FOXP3 and how it connects with Transcription factor.
The Antigen study combines topics in areas such as Cell and Tumor antigen.
His works in Monoclonal antibody and Monoclonal are all subjects of inquiry into Antibody.
He most often published in these fields:
- Molecular biology (28.84%)
- Immunology (27.12%)
- Cell biology (22.45%)
What were the highlights of his more recent work (between 2008-2021)?
- Cancer research (16.93%)
- Cell biology (22.45%)
- FOXP3 (6.56%)
In recent papers he was focusing on the following fields of study:
Mark I. Greene mostly deals with Cancer research, Cell biology, FOXP3, Immunology and Immune system.
His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Cancer, Targeted therapy, ErbB and Monoclonal antibody.
His studies deal with areas such as Molecular biology, Tyrosine kinase and Ifn gamma as well as ErbB.
The various areas that Mark I. Greene examines in his Molecular biology study include Platelet factor 4 and Cell culture.
His research in Monoclonal antibody intersects with topics in Prostate cancer and Antigen.
In his research, Antigen binding is intimately related to Biochemistry, which falls under the overarching field of Cell biology.
Between 2008 and 2021, his most popular works were:
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity (376 citations)
- Development of Foxp3+ Regulatory T Cells Is Driven by the c-Rel Enhanceosome (299 citations)
- The Ubiquitin Ligase Stub1 Negatively Modulates Regulatory T Cell Suppressive Activity by Promoting Degradation of the Transcription Factor Foxp3 (182 citations)
In his most recent research, the most cited papers focused on:
Mark I. Greene mainly investigates Cancer research, Cell biology, FOXP3, Transcription factor and Immunology.
His studies in Cancer research integrate themes in fields like Cancer cell, Cell cycle, Targeted therapy and Metastasis.
His Transcription factor research includes elements of Survivin, Immune system, Function, Regulator and Histone.
His Immunology study combines topics from a wide range of disciplines, such as Breast carcinoma and Breast disease.
His work is dedicated to discovering how Immunotherapy, Acquired immune system are connected with Antibody and other disciplines.
Mark I. Greene usually deals with Antibody and limits it to topics linked to Glycan and Prostate, Prostate cancer, Antigen and Monoclonal antibody.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
